ArticleDrug design, development and therapy2018
A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation.
Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Therapeutic Applications of Carbonic Anhydrase Inhibitors in Ophthalmology.Sub-cellular biochemistry · 2026Review
- Exploring gellan gum-based hydrogels for regenerating human embryonic stem cells in age-related macular degeneration therapy: A literature review.Regenerative therapy · 2024Review
- Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.International journal of molecular sciences · 2023Review
- Comparative Study of In Situ Gel Formulation Based on the Physico-Chemical Aspect: Systematic Review.Gels (Basel, Switzerland) · 2023Review
- Updates on Biodegradable Formulations for Ocular Drug Delivery.Pharmaceutics · 2023Review
- Biopolymers in Mucoadhesive Eye Drops for Treatment of Dry Eye and Allergic Conditions: Application and Perspectives.Pharmaceutics · 2023Review
- Preparation and Characterization of Ion-Sensitive Brimonidine Tartrate In Situ Gel for Ocular Delivery.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Hyaluronic acid-enriched bilosomes: an approach to enhance ocular delivery of agomelatine via D-optimal design: formulation,Drug delivery · 2022Article
- Injectable Hydrogel Based on Gellan Gum/Silk Sericin for Application as a Retinal Pigment Epithelium Cell Carrier.ACS omega · 2022Article
- Balsam Poplar Buds: Extraction of Potential Phenolic Compounds with Polyethylene Glycol Aqueous Solution, Thermal Sterilization of Extracts and Challenges to Their Application in Topical Ocular Formulations.Antioxidants (Basel, Switzerland) · 2022Article
- More than Antibiotics: Latest Therapeutics in the Treatment and Prevention of Ocular Surface Infections.Journal of clinical medicine · 2022Review
- In Situ Liquid Crystal Gel as a Promising Strategy for Improving Ocular Administration of Dexamethasone: Preparation, Characterization, and Evaluation.AAPS PharmSciTech · 2021Article
- Review
- Potential of Stimuli-Responsive In Situ Gel System for Sustained Ocular Drug Delivery: Recent Progress and Contemporary Research.Polymers · 2021Review
- Interactions of Meibum and Tears with Mucomimetic Polymers: A Hint towards the Interplay between the Layers of the Tear Film.International journal of molecular sciences · 2021Article
- Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions.Pharmaceutics · 2020Review
- Article
- Recent Advances in the Development of In Situ Gelling Drug Delivery Systems for Non-Parenteral Administration Routes.Pharmaceutics · 2020Review
- Biomimetic hydrogels with spatial- and temporal-controlled chemical cues for tissue engineering.Biomaterials science · 2020Review
- Advances and limitations of drug delivery systems formulated as eye drops.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
Corrections and comments
- Retraction · 2022-12-02Concerns/Issues about Image · Euphemisms for Plagiarism · Plagiarism of Image · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the study was to develop a sustained ocular delivery of brinzolamide (BLZ) based on gellan gum.
methodsThe formulations were characterized for clarity, gelling capacity, rheological studies, pH, drug content, and in vitro drug-release behavior. In vivo rabbit eye irritation test was conducted to evaluate irritation of the BLZ gel drug-delivery system. The prepared BLZ formulations were then investigated in vivo and compared with commercially available BLZ eyedrops with regard to pharmacodynamics.
resultsThe results showed that the optimum concentration of gellan gum was 0.25% w/v; the prepared liquid was converted into a flowing gel after the addition of simulated tear fluid. In vitro release profiles showed that the release of BLZ from the in situ gel exhibited sustained characteristics. Draize test results showed that BLZ in situ gels did not stimulate signs of eye tissue activity and were less irritating than BLZ solutions and commercial Azopt.
conclusionThe results of pharmacodynamics implied that the novel preparation of BLZ in situ gel effectively prolonged the intraocular pressure-lowering effect after administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.